FBRX NASDAQ
Forte Biosciences, Inc.
1W: -17.6%
1M: -38.1%
3M: -31.6%
YTD: -14.0%
1Y: +170.8%
3Y: -24.9%
5Y: -97.4%
$20.31
+0.24 (+1.20%)
Weekly Expected Move ±10.4%
$18
$21
$23
$26
$28
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$0.2M
Congress—
ETF Holdings—
Key Statistics
Market Cap$282.0M
52W Range7-35.8
Volume133,695
Avg Volume289,411
Beta3.00
Dividend—
Analyst Ratings
Company Info
CEOPaul A. Wagner
Employees14
SectorHealthcare
IndustryBiotechnology
IPO Date2017-04-13
Websitefortebiorx.com
3060 Pegasus Park Drive
Dallas, TX 75247
US
Dallas, TX 75247
US
310 618 6994
About Forte Biosciences, Inc.
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
Latest News
Forte Biosciences GAAP EPS of -$1.24
FBRX FY2026 EPS Reduced by Brookline Capital Markets
12 Health Care Stocks Moving In Thursday's Intraday Session
BlackBerry Posts Upbeat Q4 Results, Joins Constellation Brands, Marvell Technology And Other Big Stocks Moving Higher On Thursday
Forte Biosciences prices 5.71M shares at $26.27 in $150M capital raise
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Riley Antony A | M-Exempt | 375 | — | 2026-04-01 |
| Riley Antony A | F-InKind | 134 | $24.86 | 2026-04-01 |
| Riley Antony A | M-Exempt | 375 | — | 2026-04-01 |
| Wagner Paul A. | M-Exempt | 1,250 | — | 2026-04-01 |
| Wagner Paul A. | F-InKind | 98 | $24.86 | 2026-04-01 |